Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus.
Gorgojo-Martínez JJ, Mezquita-Raya P, Carretero-Gómez J, Castro A, Cebrián-Cuenca A, de Torres-Sánchez A, García-de-Lucas MD, Núñez J, Obaya JC, Soler MJ, Górriz JL, Rubio-Herrera MÁ. Gorgojo-Martínez JJ, et al. Among authors: mezquita raya p. J Clin Med. 2022 Dec 24;12(1):145. doi: 10.3390/jcm12010145. J Clin Med. 2022. PMID: 36614945 Free PMC article.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Tornøe CW, Ryan DH; SELECT Trial Investigators. Lincoff AM, et al. N Engl J Med. 2023 Dec 14;389(24):2221-2232. doi: 10.1056/NEJMoa2307563. Epub 2023 Nov 11. N Engl J Med. 2023. PMID: 37952131 Clinical Trial.
Use of Tirzepatide in Adults with Type 2 Diabetes Mellitus: Scientific Evidence and Practical Aspects.
Vázquez LA, Tofé-Povedano S, Bellido-Guerrero D, Botella-Serrano M, Soto-González A, Mezquita-Raya P, Delgado E, Fajardo-Montañana C, Morales-Portillo C, Causanilles A, Rubio-de Santos M, Romera I, Jódar-Gimeno E. Vázquez LA, et al. Among authors: mezquita raya p. Diabetes Ther. 2024 Jul;15(7):1501-1512. doi: 10.1007/s13300-024-01587-6. Epub 2024 May 9. Diabetes Ther. 2024. PMID: 38722495 Free PMC article. Review.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsbøll T; SUSTAIN-6 Investigators. Marso SP, et al. N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Free article. Clinical Trial.
Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial.
Deanfield J, Verma S, Scirica BM, Kahn SE, Emerson SS, Ryan D, Lingvay I, Colhoun HM, Plutzky J, Kosiborod MN, Hovingh GK, Hardt-Lindberg S, Frenkel O, Weeke PE, Rasmussen S, Goudev A, Lang CC, Urina-Triana M, Pietilä M, Lincoff AM; SELECT Trial Investigators. Deanfield J, et al. Lancet. 2024 Aug 24;404(10454):773-786. doi: 10.1016/S0140-6736(24)01498-3. Lancet. 2024. PMID: 39181597 Free article. Clinical Trial.
Comprehensive approach to people with type 2 diabetes. Diabetes Knowledge Area of the Spanish Society of Endocrinology and Nutrition.
Reyes-García R, Moreno-Pérez Ó, Bellido V, Botana-López M, Duran Rodríguez-Hervada A, Fernández-García D, Fernández-García JC, Gargallo-Fernández M, González-Clemente JM, Jódar-Gimeno E, López de la Torre Casares M, López-Fernández J, Marco Martínez A, Mezquita-Raya P, Rozas-Moreno P, Tejera-Pérez C, Escalada-San Martín J; members of the Diabetes Area of the SEEN. Reyes-García R, et al. Among authors: mezquita raya p. Endocrinol Diabetes Nutr (Engl Ed). 2023 Mar;70 Suppl 1:95-102. doi: 10.1016/j.endien.2023.03.002. Epub 2023 Mar 9. Endocrinol Diabetes Nutr (Engl Ed). 2023. PMID: 36906509
[Evaluation of improved nutritional status in patients over 60 years with 6-month follow-up by a nutritionist in a hospital setting in Almería. The MOR-NUT study].
Moreno Baró F, Vázquez Gutierrez M, González Carrascosa C, Muñoz de Escalona Martínez JT, Crisol Cortés MªJ, Mezquita Raya P. Moreno Baró F, et al. Among authors: mezquita raya p. Nutr Hosp. 2023 Jun 21;40(3):559-566. doi: 10.20960/nh.04278. Nutr Hosp. 2023. PMID: 36789949 Free article. Spanish.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Del Prato S, Kahn SE, Pavo I, Weerakkody GJ, Yang Z, Doupis J, Aizenberg D, Wynne AG, Riesmeyer JS, Heine RJ, Wiese RJ; SURPASS-4 Investigators. Del Prato S, et al. Lancet. 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. Lancet. 2021. PMID: 34672967 Clinical Trial.
47 results